119 related articles for article (PubMed ID: 12072584)
1. Pharmacokinetics of irbesartan are not altered in special populations.
Marino MR; Vachharajani NN
J Cardiovasc Pharmacol; 2002 Jul; 40(1):112-22. PubMed ID: 12072584
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
Kostis JB; Vachharajani NN; Hadjilambris OW; Kollia GD; Palmisano M; Marino MR
J Clin Pharmacol; 2001 Sep; 41(9):935-42. PubMed ID: 11549097
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
[TBL] [Abstract][Full Text] [Related]
4. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Brunner HR
Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.
Marino MR; Langenbacher KM; Raymond RH; Ford NF; Lasseter KC
J Clin Pharmacol; 1998 Apr; 38(4):347-56. PubMed ID: 9590462
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.
Sica DA; Marino MR; Hammett JL; Ferreira I; Gehr TW; Ford NF
Clin Pharmacol Ther; 1997 Dec; 62(6):610-8. PubMed ID: 9433389
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan.
Harada M; Kamijo Y; Nakajima T; Hashimoto K; Yamada Y; Shimojo H; Gonzalez FJ; Aoyama T
Clin Sci (Lond); 2016 Nov; 130(21):1969-1981. PubMed ID: 27496805
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
[TBL] [Abstract][Full Text] [Related]
9. The effects of age and gender on the pharmacokinetics of irbesartan.
Vachharajani NN; Shyu WC; Smith RA; Greene DS
Br J Clin Pharmacol; 1998 Dec; 46(6):611-3. PubMed ID: 9862252
[TBL] [Abstract][Full Text] [Related]
10. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Wang B; Xu X; Wang X
Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
[TBL] [Abstract][Full Text] [Related]
11. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
[TBL] [Abstract][Full Text] [Related]
12. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
13. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
Zhang S; Liu P; Jiang S; Hong X; Xing H; Xu X
Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
Gillis JC; Markham A
Drugs; 1997 Dec; 54(6):885-902. PubMed ID: 9421695
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
[TBL] [Abstract][Full Text] [Related]
17. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
Anusha A; Narendar D; Krishna Murthy B; Goverdhan P
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):179-185. PubMed ID: 28386752
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
19. Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.
Gu S; Chen H; Qiu Y; Shi S; Zeng F
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):14-6. PubMed ID: 12658772
[TBL] [Abstract][Full Text] [Related]
20. Irbesartan: an updated review of its use in cardiovascular disorders.
Markham A; Spencer CM; Jarvis B
Drugs; 2000 May; 59(5):1187-206. PubMed ID: 10852648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
